Videos

FOURIER update: new impetus for guideline groups to reconsider LDL targets

Is lowering lipoprotein(a) beneficial when LDL-C is very low?

VIDEO: How best to optimise PCSK9 inhibition, considering findings from FOURIER and ODYSSEY Outcomes

Professor Gaetano De Ferrari (University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy) discusses the importance of patient characteristics, and the timing and history of vascular disease.

VIDEO: What’s in the PCSK9 pipeline?

PCSK9 antibody therapy is indisputably effective, well tolerated and improves clinical outcomes; however, cost is an issue. PCSK9 Forum Editor Professor Derick Raal (University of Witwatersrand, Johnannesburg, South Africa) discusses what to look forward to after the PCSK9 monoclonal antibodies.

VIDEO: EAS Congress: Lowering lipoprotein(a) for clinical benefit: How much?

Professor Henry Ginsberg (Columbia University, New York, USA) discusses the late breaker genetics analysis reported at EAS Congress.

EAS Consensus Panel: Statins do not impair cognitive function

EAS Panel Co-Chair discusses the evidence-based conclusions from this latest EAS Consensus Panel statement on adverse effects of statin therapy, focusing on effects on cognitive function.

EAS Congress: FOURIER analysis shows benefit of PCSK9 inhibition in patients with elevated lipoprotein(a)

Dr Michelle O’Donogue (Brigham and Women’s Hospital, Boston, USA) discusses the key findings from this FOURIER analysis and what it means for patients

The Word from ACC 2018: ODYSSEY Outcomes

Highlights from ACC.2018: Poster presentations

Real-life experience with PCSK9 inhibition in familial hypercholesterolaemia Familial hypercholesteraemia (FH, inherited high cholesterol) is one of the key groups for whom PCSK9 inhibition is indicated. This prospective registry provided data on 44 patients with genetically verified FH attending a specialist lipid clinic in Norway….

VIDEO: Will the trial evidence now overcome barriers to the use of PCSK9 inhibition?

Will FOURIER and ODYSSEY Outcomes change LDL cholesterol goals in high-risk patients?

VIDEO: Do FOURIER and ODYSSEY Outcomes align with the ESC/EAS Task Force guidance on practical use of PCSK9 inhibition?

Professor Stephen Nicholls (South Australian Health and Medical Research Institute, Adelaide, Australia): How do you interpret the mortality data from ODYSSEY Outcomes?

Professor Stephen Nicholls (South Australian Health and Medical Research Institute, Adelaide, Australia): Would you have expected a greater magnitude of benefit for the primary outcome in ODYSSEY Outcomes?

Professor Raul Santos (University of São Paulo, Brazil): Why was the mortality benefit in ODYSSEY Outcomes only evident after 1 year of follow-up?

Professor Raul Santos (University of São Paulo, Brazil): What are the key take home messages from ODYSSEY Outcomes?

Will ODYSSEY Outcomes change the management of ACS patients?

What is the take home message from ODYSSEY Outcomes regarding the role of LDL cholesterol in CVD prevention?

How do you explain the different mortality results in ODYSSEY Outcomes versus FOURIER?

Does ODYSSEY Outcomes align with FOURIER and the SPIRE cardiovascular outcomes studies?